Trinity Biotech

Trinity Biotech EBIT CAGR 3Y

The EBIT CAGR (3 Year) of Trinity Biotech (TRIB) as of Nov 10, 2026 is -9.24 %. In the previous year, EBIT CAGR (3 Year) was -9.24 % — a change of 0.00% (lower).

EBIT CAGR 3Y

-9.24 %

YoY

0.00%

Last updated:

EBIT CAGR (3 Year) of Trinity Biotech is 2025 -9.24 % . EBIT CAGR (3 Year) of Trinity Biotech was 2024 -9.24 % . It decreases by 0.00% lower compared to the previous year.

The Trinity Biotech EBIT CAGR 3Y history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT CAGR 3Y
Date
EBIT CAGR 3Y
Jan 1, 2018
-9.24 USD
Jan 1, 2019
-9.24 USD
Jan 1, 2020
-9.24 USD
Jan 1, 2021
-9.24 USD
Jan 1, 2022
-9.24 USD
Jan 1, 2023
-9.24 USD
Jan 1, 2024
-9.24 USD
Jan 1, 2025
-9.24 USD
The Trinity Biotech EBIT CAGR 3Y history
YEAREBIT CAGR 3YYoY
-9.24 %0.00%
-9.24 %0.00%
-9.24 %0.00%
-9.24 %0.00%
-9.24 %0.00%
-9.24 %0.00%
-9.24 %0.00%
-9.24 %0.00%
-9.24 %0.00%
-9.24 %0.00%
-9.24 %0.00%
-9.24 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

EBIT CAGR (3 Year) of Trinity Biotech is -9.24 % in 2025.

On Eulerpool you can find the complete historical development of EBIT CAGR (3 Year) Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

The 3-year EBIT CAGR shows the compound annual growth rate of EBIT over the past three years.

To evaluate EBIT CAGR (3 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT CAGR (3 Year).

EBIT CAGR (3 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT CAGR (3 Year)'s Trinity Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Trinity Biotech

All Key Metrics — Trinity Biotech